Cigna Corporation (CI) Balance Sheet

The 2.6% year-over-year asset growth is modest but consistent, driven by higher receivables and intangibles from the services segment. Equity increased to $42.6B, a 3.2% rise from Q2 2025, suggesting retained earnings are accumulating despite the MA divestiture. This trajectory indicates a balance sheet that is expanding in line with revenue growth, though the pace is slower than the 6.6% revenue increase, implying some asset efficiency gains.

The absence of meaningful investment data limits the ability to assess asset allocation, duration, or unrealized positions. Given the insurance model, the investment portfolio is typically a key earnings driver, but here it appears immaterial or unreported. Investors should seek additional disclosures to evaluate the quality and yield of the invested assets, especially in a rising rate environment.

The sharp drop in loss ratio from 90.6% in Q1 to 79.1% in Q2, despite higher reserves, suggests favorable prior-year development may be boosting earnings. This is consistent with the cash flow analysis showing negative operating cash flow, indicating that reported earnings are not fully backed by cash. The reserve build may reflect higher IBNR estimates, but the divergence between earnings and cash warrants close monitoring.

The equity growth is modest but steady, supported by retained earnings despite the planned sale of the Medicare Advantage business. The low debt-to-equity ratio, though suspiciously low for an insurer, suggests ample capital headroom for buybacks or M&A. However, the pending MA divestiture will free up capital, but the deployment strategy remains unclear, and investors should watch for any changes in leverage.

The negative operating cash flow, despite a low loss ratio, indicates that cash outflows for claims are outpacing premium collections, possibly due to timing or reserve releases. This suggests a tighter liquidity position, though the company maintains access to capital markets. The lack of cash data limits a full assessment, but the trend warrants attention.

The forward visibility is clouded by the potential for PBM rebate reforms, which could compress margins in the health services segment. The recent earnings beat and guidance raise suggest near-term confidence, but the structural risks remain. Investors should monitor the MA divestiture closing and any regulatory developments that could impact reserve adequacy or premium trends.